Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Cilostazol
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 22 results found since Jan 2013.
Do the Antithrombotic Therapy at the Time of Intracerebral Hemorrhage Influence Clinical Outcome? Analysis between the Difference of Antiplatelet and Anticoagulant Agents and Clinical Course
Background: It is controversial whether taking antiplatelet agents (APs) or anticoagulant agents (ACs) could influence clinical outcome after intracerebral hemorrhage (ICH).Methods: We retrospectively investigated 557 ICH patients between September 2008 and August 2013. We reviewed patients' characteristics, hematoma volume, deterioration (hematoma expansion, surgical hematoma evacuation, or death), and clinical outcome in modified Rankin Scale.Results: A total of 397 were classified as neither AP nor AC (“Nothing”), 81 as single AP (44 as aspirin [ASA], 22 as clopidogrel or ticlopidine [CLP/TIC], 7 as cilostazol, 8 as...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Takeshi Okada, Taizen Nakase, Masahiro Sasaki, Tatsuya Ishikawa Tags: Original Articles Source Type: research
Carotid Plaque Characteristics on Magnetic Resonance Plaque Imaging Following Long-term Cilostazol Therapy
Conclusions: Signal alterations on MR plaque imaging indicated the increase of fibrous components and the decrease of lipid/necrotic components in the carotid plaque during the cilostazol therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - August 29, 2014 Category: Neurology Authors: Mao Yamaguchi Oura, Makoto Sasaki, Hideki Ohba, Shinsuke Narumi, Kazumasa Oura, Ikuko Uwano, Yasuo Terayama Tags: Original Articles Source Type: research
The Effect of Acute Medication with Cilostazol, an Anti-platelet Drug, on the Outcome of Small Vessel Brain Infarction
Source: Journal of Stroke and Cerebrovascular Diseases - February 10, 2014 Category: Neurology Authors: Taizen Nakase, Masahiro Sasaki, Akifumi Suzuki Tags: Original Articles Source Type: research
Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study
The mechanism of progressive neurological deficit in patients with recent small subcortical infarcts has not yet been clarified. Inflammatory biomarkers and the use of cilostazol may be associated with this phenomenon.
Source: Journal of Stroke and Cerebrovascular Diseases - February 14, 2018 Category: Neurology Authors: Naoki Saji, Shigenobu Tone, Kenta Murotani, Yoshiki Yagita, Kazumi Kimura, Takashi Sakurai Source Type: research
Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis
Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage considering its anti-platelet and vasodilatory effects. We aimed to analyze the effects of cilostazol on symptomatic vasospasm and clinical outcome among patients with aneurysmal subarachnoid hemorrhage (aSAH).
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Hamidreza Saber, Aaron Desai, Mohan Palla, Wazim Mohamed, Navid Seraji-Bozorgzad, Muhammed Ibrahim Source Type: research
Comparison of Effects between Clopidogrel and Cilostazol on Cerebral Perfusion in Nonsurgical Adult Patients with Symptomatically Ischemic Moyamoya Disease: Subanalysis of a Prospective Cohort
Adult patients with symptomatically ischemic moyamoya disease (MMD) initially undergo medical treatment alone including antiplatelet drugs when symptomatic cerebral hemispheres do not exhibit hemodynamic compromise. The purpose of the present study subanalyzing the same patient cohort used in a previous study was to determine which antiplatelet drug, clopidogrel or cilostazol, provides better improvement of cerebral perfusion in such patients.
Source: Journal of Stroke and Cerebrovascular Diseases - August 31, 2018 Category: Neurology Authors: Takayuki Chiba, Kengo Setta, Yasuyoshi Shimada, Jun Yoshida, Kentaro Fujimoto, Shouta Tsutsui, Kenji Yoshida, Masakazu Kobayashi, Yoshitaka Kubo, Shunrou Fujiwara, Kazunori Terasaki, Kuniaki Ogasawara Source Type: research
